Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
27,461
archived clinical trials in
Hematology

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Trinity Medical Center
mi
from
Moline, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Trinity Medical Center
mi
from
Moline, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare - Monmouth
mi
from
Monmouth, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Good Samaritan Regional Health Center
mi
from
Mount Vernon, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Good Samaritan Regional Health Center
mi
from
Mount Vernon, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare-Ottawa Clinic
mi
from
Ottawa, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare - Pekin
mi
from
Pekin, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare - Pekin
mi
from
Pekin, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Methodist Medical Center of Illinois
mi
from
Peoria, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
OSF Saint Francis Medical Center
mi
from
Peoria, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare - Peru
mi
from
Peru, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare - Peru
mi
from
Peru, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Illinois CancerCare - Princeton
mi
from
Princeton, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Illinois CancerCare - Princeton
mi
from
Princeton, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
SwedishAmerican Regional Cancer Center/ACT
mi
from
Rockford, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
SwedishAmerican Regional Cancer Center/ACT
mi
from
Rockford, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Memorial Medical Center
mi
from
Springfield, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Memorial Medical Center
mi
from
Springfield, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Carle Cancer Center
mi
from
Urbana, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Carle Cancer Center
mi
from
Urbana, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Carle Foundation Hospital
mi
from
Urbana, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Carle Foundation Hospital
mi
from
Urbana, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Rush-Copley Healthcare Center
mi
from
Yorkville, IL
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Rush-Copley Healthcare Center
mi
from
Yorkville, IL
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Franciscan Saint Anthony Health-Michigan City
mi
from
Michigan City, IN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Franciscan Saint Anthony Health-Michigan City
mi
from
Michigan City, IN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Woodland Cancer Care Center
mi
from
Michigan City, IN
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Woodland Cancer Care Center
mi
from
Michigan City, IN
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mary Greeley Medical Center
mi
from
Ames, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mary Greeley Medical Center
mi
from
Ames, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
McFarland Clinic PC-William R Bliss Cancer Center
mi
from
Ames, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Constantinou, Costas L MD
mi
from
Bettendorf, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Constantinou, Costas L MD
mi
from
Bettendorf, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Hematology Oncology Associates of the Quad Cities
mi
from
Bettendorf, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
McFarland Clinic PC-Boone
mi
from
Boone, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
McFarland Clinic PC-Boone
mi
from
Boone, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Medical Oncology and Hematology Associates-West Des Moines
mi
from
Clive, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Cancer Center - West Lakes
mi
from
Clive, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Genesis Medical Center - East Campus
mi
from
Davenport, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Genesis Medical Center - East Campus
mi
from
Davenport, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Iowa Methodist Medical Center
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Medical Oncology and Hematology Associates-Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Medical Oncology and Hematology Associates-Laurel
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Medical Center - Des Moines
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Iowa Lutheran Hospital
mi
from
Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
McFarland Clinic PC-Trinity Cancer Center
mi
from
Fort Dodge, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
McFarland Clinic PC-Trinity Cancer Center
mi
from
Fort Dodge, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
McFarland Clinic PC-Jefferson
mi
from
Jefferson, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
McFarland Clinic PC-Jefferson
mi
from
Jefferson, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
McFarland Clinic PC-Marshalltown
mi
from
Marshalltown, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
McFarland Clinic PC-Marshalltown
mi
from
Marshalltown, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Saint Luke's Regional Medical Center
mi
from
Sioux City, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Methodist West Hospital
mi
from
West Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Methodist West Hospital
mi
from
West Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Mercy Medical Center-West Lakes
mi
from
West Des Moines, IA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas - Fort Scott
mi
from
Fort Scott, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas-Independence
mi
from
Independence, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas-Independence
mi
from
Independence, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Kingman
mi
from
Kingman, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Lawrence Memorial Hospital
mi
from
Lawrence, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Lawrence Memorial Hospital
mi
from
Lawrence, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Liberal
mi
from
Liberal, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas-Manhattan
mi
from
Manhattan, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas-Manhattan
mi
from
Manhattan, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - McPherson
mi
from
McPherson, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Newton
mi
from
Newton, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Parsons
mi
from
Parsons, KA
Click here to add this to my saved trials
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated:  3/6/2018
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients With Relapsed or Refractory Disease
Status: Enrolling
Updated: 3/6/2018
Cancer Center of Kansas, PA - Pratt
mi
from
Pratt, KA
Click here to add this to my saved trials